Co-Diagnostics, Inc.
  • ABOUT
    • Locations
      • Salt Lake City, Utah
      • Gujarat, India
    • CoSara Diagnostics Private Limited
    • Videos & Multimedia
    • Management
  • PRODUCTS
    • Diagnostic Solutions
      • Logix Smart™ MTB
      • Logix Smart™ Zika
      • Logix Smart™ ZDC
      • Logix Smart™ COVID-19
      • Logix Smart™ SARS-CoV-2 (RdRp/E)
      • Logix Smart™ SARS-CoV-2 DS
      • Logix Smart™ ABC
    • Research Solutions
      • Logix Smart 2019-nCoV
    • Vector Control Solutions
    • Agricultural Solutions
    • Equipment
    • CoPrimers™/CODX™ Design Services
    • Email Alerts
  • APPLICATIONS
    • Screenings & Detection
    • Multiplexing
    • SNP Detection
    • Next-Gen Sequencing
    • Liquid Biopsy
  • TECHNOLOGY
    • What is PCR?
    • History
    • CoPrimers™
    • RapidProbes™
    • Hot Start
    • CoDx Design™ Process
  • Newsroom
    • Press Releases
    • In The News
    • Media Resources
      • RSS
  • INVESTORS
    • Events-Webcasts
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • SEC filings
    • Financial Information
      • Key Ratios
    • Corporate Governance
      • Board Committees
    • Investor Resources
  • Resources
    • Terms And Conditions For Sales
    • Instructions For Use
    • Safety Data Sheets
    • Instructional Videos
    • Troubleshooting
    • Publications
  • CONTACT
Select Page

Co-Diagnostics, Inc. Completes Submission of CE Mark Registration for Zika/Dengue/Chikungunya Multiplex Test

by Co-Diagnostics | Feb 26, 2019 | News Release

Company’s multiplexed Logix Smart™ ZDC Test to be available for purchase with CE mark in March 2019 Salt Lake City, Utah – February 26, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the...

Co-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards

by Co-Diagnostics | Feb 22, 2019 | News Release

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has received written notice from the Nasdaq...

Co-Diagnostics, Inc. Announces Mosquito Vector Control Training Course in the Dominican Republic

by Co-Diagnostics | Feb 21, 2019 | News Release

Trainings will be conducted for staff and customers of Laboratorios Franja, including demonstrations of Company’s vector control products SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique,...

Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering

by Co-Diagnostics | Feb 4, 2019 | News Release

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced offering. In a...

Follow us on Facebook

https://www.facebook.com/codiagnostics/

Recent Comments

    About Co-Diagnostics

    Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our molecular diagnostics development platform is marketed under the brand name CoDx™. CoDx products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

     

    Click here to learn more
    design by TYMcreative